Kenneth L. Davis, MD | |
|---|---|
 | |
| Nationality | American |
| Education | Mount Sinai School of Medicine, Stanford University School of Medicine, Stanford University Hospital |
| Occupation(s) | Executive vice chairperson of the board of trustees at the Mount Sinai Health System |
| Known for | Psychiatry |
| Medical career | |
| Field | Psychiatry, Alzheimer's disease, schizophrenia |
| Institutions | Mount Sinai Health System |
| Notable works | Alzheimer's Disease Assessment Scale |
| Awards | George H. W. Bush Lifetime of Leadership Award |
| Website | Kenneth L. Davis, MD |
Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City,[1][2] and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease.[3][4] His research led to four of the first five FDA-approved drugs for Alzheimer's.[5]
- ^ "Mount Sinai Boards of Trustees Announce Updated Leadership Structure | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2021-11-09.
- ^ Neber, Jaqueline (November 21, 2023). "Mount Sinai Health System names Dr. Brendan Carr as next CEO". Craine's New York Business. Retrieved January 14, 2023.
- ^ A new rating scale for Alzheimer's disease, American Journal of Psychiatry
- ^ "Mt Sinai Hospital -- IRS Form 990 2017". Pro Publica Non Profit Explorer. 9 May 2013. Retrieved July 1, 2019.
- ^ "How Dr. Kenneth Davis Turned the Mount Sinai Health System Around". 1A. Retrieved 2022-04-27.